Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Drug Delivery

PAREXEL agrees to acquire ExecuPharm PAREXEL International has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry.
Drug Research > Drug Delivery > News
UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.
Drug Research > Drug Delivery > News Facebook’s Mark Zuckerberg announces $3bn funding to help cure diseases By PBR Staff Writer
Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, have committed to invest over $3bn during the next decade to work on preventing, curing or managing all diseases.
Drug Research > Drug Delivery > News
See more Drug Delivery news

Latest Drug Delivery News and Insight

View all Drug Delivery news or find news targeted to your interests
UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq
By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.
Drug Research > Drug Delivery > News
Facebook’s Mark Zuckerberg announces $3bn funding to help cure diseases
By PBR Staff Writer
Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, have committed to invest over $3bn during the next decade to work on preventing, curing or managing all diseases.
Drug Research > Drug Delivery > News
EMA validates BMS' type II variation application for Opdivo in advanced form of bladder cancer
The European Medicines Agency (EMA) validated Bristol-Myers Squibb's (BMS) type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
Drug Research > Drug Delivery > News
Catalent agrees to buy Pharmatek Laboratories
By PBR Staff Writer
Drug delivery solutions provider Catalent has agreed to acquire Pharmatek Laboratories, a US-based contract drug development and clinical manufacturing firm, for an undisclosed sum.
Drug Research > Drug Delivery > News
ImmuPharma to open site in Mauritius for trial of Lupus treatment
ImmuPharma has provided a further update on the progress of its Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
Drug Research > Drug Delivery > News
Dr. Reddy's Laboratories launches Bupropion HCl extended-release tablets, USP (SR) in US
Dr. Reddy’s Laboratories has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCl) Sustained-Release Tablets in the US market approved by the US Food & Drug Administration (USFDA).
Drug Research > Drug Delivery > News
Caisson Biotech seeks buyer for HEPtune drug-delivery platform
Caisson Biotech has appointed Pickwick Capital Partners to assist in the sale of the HEPtune drug-delivery platform.
Drug Research > Drug Delivery > News
View all Drug Delivery news or find news targeted to your interests